^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
LY3381916
i
Other names: LY 3381916, LY3381916
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Eli Lilly
Drug class:
IDO1 inhibitor
Related drugs:
over3years
A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer. (PubMed, J Immunother)
These preliminary data suggest an alternative dose level of LY3381916 is needed for the combination with PD-L1 inhibitor. The combination clinical activity was limited in this study.
Clinical • P1 data • Journal • Combination therapy
|
CD8 (cluster of differentiation 8) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
lodapolimab (LY3300054) • LY3381916
5years
A phase I study of an anti-IDO1 inhibitor (LY3381916) as monotherapy and in combination with an anti-PD-L1 antibody (LY3300054) in patients with advanced cancer (ESMO-IO 2019)
LY3381916 is safely administered as monotherapy and in combination with LY3300054. The 240mg dose QD is the RP2D for combination with PD-L1 in expansion cohorts.Legal entity responsible for the study: Eli Lilly and Company. Funding: Eli Lilly and Company.
Clinical • P1 data • Combination therapy • PD(L)-1 Biomarker • IO biomarker
|
CD8 (cluster of differentiation 8) • IDO1 (Indoleamine 2,3-dioxygenase 1)
|
lodapolimab (LY3300054) • LY3381916
Share via
